Cargando…
Tyrosine Kinase Inhibitors and Proton Pump Inhibitors: An Evaluation of Treatment Options
Tyrosine kinase inhibitors (TKIs) have rapidly become an established factor in oncology, and have been shown to be effective in a wide variety of solid and hematologic malignancies. Use of the oral administration route of TKIs offers flexibility and is convenient for the patient; however, despite th...
Autores principales: | van Leeuwen, Roelof W. F., Jansman, Frank G. A., Hunfeld, Nicole G., Peric, Robert, Reyners, Anna K. L., Imholz, Alex L. T., Brouwers, Jacobus R. B. J., Aerts, Joachim G., van Gelder, Teun, Mathijssen, Ron H. J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5488129/ https://www.ncbi.nlm.nih.gov/pubmed/28101705 http://dx.doi.org/10.1007/s40262-016-0503-3 |
Ejemplares similares
-
Clinically relevant drug interactions with multikinase inhibitors: a review
por: Hussaarts, Koen G. A. M., et al.
Publicado: (2019) -
Influence of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib: A Randomized Crossover Pharmacokinetic Study
por: de Man, Femke M., et al.
Publicado: (2019) -
The Risk of QTc-Interval Prolongation in Breast Cancer Patients Treated with Tamoxifen in Combination with Serotonin Reuptake Inhibitors
por: Hussaarts, Koen G. A. M., et al.
Publicado: (2019) -
Proton Pump Inhibitors are Risk Factors for Viral Infections: Even for COVID-19?
por: Charpiat, Bruno, et al.
Publicado: (2020) -
Safe use of proton pump inhibitors in patients with cirrhosis
por: Weersink, Rianne A., et al.
Publicado: (2018)